These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 34355250)
1. A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects. Hanes V; Chow V; Stewart T; Puri A Cancer Chemother Pharmacol; 2021 Nov; 88(5):879-886. PubMed ID: 34355250 [TBL] [Abstract][Full Text] [Related]
2. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. Kolberg HC; Colleoni M; Demetriou GS; Santi P; Tesch H; Fujiwara Y; Tomasevic Z; Hanes V Drug Saf; 2020 Mar; 43(3):233-242. PubMed ID: 31927716 [TBL] [Abstract][Full Text] [Related]
3. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C; Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420 [TBL] [Abstract][Full Text] [Related]
4. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636 [TBL] [Abstract][Full Text] [Related]
5. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers. Zhou H; Cao S; Zhu X; Xie J; Fan L; Ge Q; Wang Y; Zhu J; Liu Y; Shao Z; Shan R; Liu B; Wang H; Ding L Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):997-1003. PubMed ID: 32847423 [TBL] [Abstract][Full Text] [Related]
6. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Hanes V; Chow V; Zhang N; Markus R Cancer Chemother Pharmacol; 2017 May; 79(5):881-888. PubMed ID: 28341959 [TBL] [Abstract][Full Text] [Related]
7. TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin Demarchi M; Coliat P; Mclendon K; Chung Shii Hii J; Feyaerts P; Ang F; Jaison L; Deforce F; Derde MP; Kim MJ; Park LS; Detappe A; Pivot X Pharmacol Res Perspect; 2021 Aug; 9(4):e00839. PubMed ID: 34309241 [TBL] [Abstract][Full Text] [Related]
8. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. Alexeev SM; Khorinko AV; Mukhametshina GZ; Shelepen KG; Burdaeva ON; Kulik SA; Satheesh CT; Srivastava K; Vikranth M; Kryukov F; Paltusova AN; Shustova MS; Ivanov RA BMC Cancer; 2020 Aug; 20(1):783. PubMed ID: 32819305 [TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin Lickliter JD; Dadhania RN; Trivedi RK; Naveen Kumar SR; Reddy PK Indian J Med Res; 2021 Mar; 154(3):509-519. PubMed ID: 35142643 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects. Chow V; Oh M; Gessner MA; Fanjiang G Clin Pharmacol Drug Dev; 2020 Feb; 9(2):246-255. PubMed ID: 31628783 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292 [TBL] [Abstract][Full Text] [Related]
12. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980 [TBL] [Abstract][Full Text] [Related]
13. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects. Hanes V; Chow V; Pan Z; Markus R Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275 [TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer. Kothari R; Doshi M; Chaithanya PK; Ct S; Kumar A; Mallavarapu KM; Nagarkar R; Mahobia V; Bhatt N; Priyadarshini KL; Gogia A; Maksud T; Prasad S; Velavan K; L K R; Ss P; Talreja V; Kalra K; Nemade B; Dastidar AG; Gupta T; Patil T; Bondarde S; Patel P; Gupta S; Biswas G; Vaghela M; Mahato P; Parekh H; Kalloli M; Shetty R; Prakash G; Goel A; Mandal S; Choudhury T; Jain M; Goswami C; H M YK; Mukherjee KK; Shrivastava R; Parmar D Clin Breast Cancer; 2024 Oct; 24(7):639-646.e2. PubMed ID: 39069436 [TBL] [Abstract][Full Text] [Related]
15. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study. Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763 [TBL] [Abstract][Full Text] [Related]
16. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects. Zhu X; Ding Y; Yu Y; Wang M; Zhou W; Wang J; Zhu X; Zhang H; Wang M; Chai K; Zhang X; Luk A; Jiang W; Liu S; Zhang Q Cancer Chemother Pharmacol; 2021 Mar; 87(3):349-359. PubMed ID: 33169186 [TBL] [Abstract][Full Text] [Related]
17. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers. Wisman LA; De Cock EP; Reijers JA; Kamerling IM; Van Os SH; de Kam ML; Burggraaf J; Voortman G Clin Drug Investig; 2014 Dec; 34(12):887-94. PubMed ID: 25377592 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects. Farmahini Farahani M; Maghzi P; Jafari Aryan N; Payandemehr B; Soni M; Azhdarzadeh M Expert Opin Investig Drugs; 2020 Dec; 29(12):1443-1450. PubMed ID: 33016783 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin Chen X; Li C; Ewesuedo R; Yin D Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945 [TBL] [Abstract][Full Text] [Related]
20. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Kaur P; Chow V; Zhang N; Moxness M; Kaliyaperumal A; Markus R Ann Rheum Dis; 2017 Mar; 76(3):526-533. PubMed ID: 27466231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]